These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32475050)

  • 1. Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease.
    Kikuchi N; Ogawa H; Kawada-Watanabe E; Arashi H; Jujo K; Sekiguchi H; Yamaguchi J; Hagiwara N
    J Clin Hypertens (Greenwich); 2020 Jun; 22(6):1070-1079. PubMed ID: 32475050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of left ventricular ejection function on blood pressure-lowering therapy in hypertensive patients with coronary artery disease.
    Kikuchi N; Jujo K; Yamaguchi J; Ogawa H; Hagiwara N
    J Hypertens; 2016 May; 34(5):1011-8. PubMed ID: 26882041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of visit-to-visit variability and systolic blood pressure control on subsequent outcomes in hypertensive patients with coronary artery disease (from the HIJ-CREATE substudy).
    Arashi H; Ogawa H; Yamaguchi J; Kawada-Watanabe E; Hagiwara N
    Am J Cardiol; 2015 Jul; 116(2):236-42. PubMed ID: 25966826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
    Sugiura R; Ogawa H; Oka T; Koyanagi R; Hagiwara N;
    Am J Cardiol; 2012 Feb; 109(4):576-80. PubMed ID: 22100194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study.
    Kamishima K; Ogawa H; Jujo K; Yamaguchi J; Hagiwara N
    Diabetes Res Clin Pract; 2019 Mar; 149():69-77. PubMed ID: 30735770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Fujimoto A; Ueshima K; Oba K; Shimamoto K; Matsuoka H; Saruta T;
    Hypertens Res; 2008 Aug; 31(8):1595-601. PubMed ID: 18971535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Blood Pressure in Patients With Coronary Artery Disease and Chronic Kidney Disease: HIJ-CREATE Substudy.
    Tanaka K; Jujo K; Yamaguchi J; Ogawa H; Hagiwara N
    Am J Med Sci; 2019 Sep; 358(3):219-226. PubMed ID: 31324360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
    Fukui T; Rahman M; Hayashi K; Takeda K; Higaki J; Sato T; Fukushima M; Sakamoto J; Morita S; Ogihara T; Fukiyama K; Fujishima M; Saruta T;
    Hypertens Res; 2003 Dec; 26(12):979-90. PubMed ID: 14717341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.
    Fernández-Vega F; Abellán J; Vegazo O; De Vinuesa SG; Rodríguez JC; Maceira B; de Castro SS; Nicolás RR; Luño J
    Kidney Int Suppl; 2002 Dec; (82):S36-41. PubMed ID: 12410853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could intensive anti-hypertensive therapy produce the "J-curve effect" in patients with coronary artery disease and hypertension after revascularization?
    Lu W
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1350-5. PubMed ID: 27097958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.